Literature DB >> 415919

The effect of Corynebacterium parvum on the proliferation of monocyte precursors in the bone marrow of mice.

M J Chare, M Baum.   

Abstract

The anti-tumour activity of C. parvum is thought to be mediated via the monocyte/macrophage system (Scott, 1974). These cells originate from rapidly dividing precursors in the bone marrow and it might be at this level that C. parvum exerts its action. To test this hypothesis bone marrow T0 Swiss mice has been cultured according to the method of Bradley and Metcalf (1966), which gives an index of the number of proliferating macrophage precursor cells at the time of sacrifice. Experiments were set up at various times following a single i.p. injection of 700 microgram of an anti-tumour strain of C. parvum (CN 6134-Wellcome Research Laboratories). Controls received 700 microgram of either C. diphtheriae CN 2000 or C. parvum CN 5888, a strain with no anti-tumour activity. Macrophage colony counts in those mice receiving "active" C. parvum were significantly higher than those in controls at intervals from 2 h to 3 weeks post-treatment. This time course parallels certain immunological properties of C. parvum and suggests a possible mode of action.

Entities:  

Mesh:

Year:  1977        PMID: 415919

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  3 in total

1.  Small-cell lung cancer and immunochemotherapy with Propionibacterium granulosum KP 45.

Authors:  K Roszkowski; B Nozdryn-Plotnicki; W Roszkowski; H L Ko; J Jeljaszewicz; G Pulverer
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

2.  Immunochemotherapy of breast cancer with Propionibacterium granulosum.

Authors:  K Roszkowski; B Nozdryn-Plotnicki; W Roszkowski; H L Ko; G Pulverer; J Jeljaszewicz
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

3.  Effect of intravenous corynebacterium parvum on peripheral-blood effector cells of cancer patients.

Authors:  P G Gill; C A Waller; I C MacClennan; P J Morris
Journal:  Br J Cancer       Date:  1980-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.